Hackensack Meridian Mountainside Medical Center has been approved to use Pluvicto, an FDA-approved, targeted radioligand therapy for treatment of metastatic prostate-specific membrane antigen positive castration-resistant prostate cancer (PSMA+ mCRPC).
Studies show that patients treated with Pluvicto, after treatment with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy, had a 38% reduction in risk of death compared to AR pathway inhibition and chemotherapy alone. According to the American Cancer Society, prostate cancer is the most common cancer in American men, with an estimated 268,490 new cases and 34,500 deaths projected for 2022.
In July of this year, Mountainside Medical Center was among one of the first hospitals in Northern New Jersey to offer prostate cancer targeted Positron Emission Tomography (PET Imaging) with Illucix, a Prostate-Specific Membrane Antigen (PSMA) imaging agent.
